Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 23 May 2025, 16:29 HKT/SGT
Share:
    

Source: Fujitsu Ltd
Fujitsu and Tokai National Higher Education and Research System utilize AI to accelerate clinical research and tackle 'drug loss' in Japan
Streamlining patient selection for clinical trials, improving efficiency and enabling better use of real-world data

Kawasaki and Nagoya, Japan, May 23, 2025 - (JCN Newswire) - Fujitsu Limited and Tokai National Higher Education and Research System (THERS) today announced the successful completion of field trials using generative AI to process clinical data for use in the selection of clinical trial participants. The effort aims to address the issue ‘drug loss’ in Japan, i.e., a lack of availability of drugs used overseas due to stringent local approval requirements.

In a clinical setting patient data can be broadly seperated into structured data, i.e., organized and quantifiable data such as vital signs and lab results, and unstructured data, i.e., data that lacks a predefined format such as doctors’ notes. Structuring unstructured clinical data has traditionally been a time-consuming manual process. These field trials used data from approximately 1,800 patient records of breast surgery procedures obtained from Nagoya University and Gifu University. Unstructured data was successfully structured at approximately 90% accuracy. Leveraging this newly structured data, a screening of three clinical trial projects identified 42 potential candidates, 27 of whom were actually eligible, potentially reducing patient selection time by approximately one-third. This enables faster decision-making and increases patient access to optimal clinical trials. Moving forward, both organizations will work to expand the number of target diseases and participating facilities, and improve the accuracy of this approach, while promoting its use in actual clinical trials.

Fujitsu and THERS will further link the results of these field trials with Paradigm Health, Inc.’s state-of-the-art clinical trial platform to accelerate the use of real-world data (RWD). This will enable collaboration with medical institutions and pharmaceutical companies to enhance the planning and overall execution of clinical trials, and help mitigate drug loss in Japan.

Future Plans

THERS aims to actively attract international joint clinical trials to the Japanese Tokai region and improve patients medical care by increasing operational efficiency and utilizing a clinical research environment for handling high-quality clinical data.

On May 30, based on the results of these field trials, Fujitsu will expand its Healthy Living Platform and launch a function to promote the structuring and utilization of medical data using its AI service Fujitsu Kozuchi. This function will also be linked with the enterprise large language model (LLM) Takane in the future to support the advancement of data analysis in clinical research and the efficiency of patient selection.

Fujitsu will continue to contribute to improving the overall performance of clinical research and the development of medical care in Japan under Fujitsu Uvance, its business model oriented around solving societal issues.

About Fujitsu

Fujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.

Press Contacts
Fujitsu Limited
Public and Investor Relations Division
Inquiries




Topic: Press release summary
Source: Fujitsu Ltd

Sectors: Enterprise IT, Artificial Intel [AI]
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Fujitsu Ltd Links

http://www.fujitsu.com

https://plus.google.com/+Fujitsu

https://www.facebook.com/FujitsuJapan

https://twitter.com/Fujitsu_Global

https://www.youtube.com/user/FujitsuOfficial

https://www.linkedin.com/company/fujitsu/

Fujitsu Ltd
Sept 29, 2025 13:06 HKT/SGT
Fujitsu and AIST sign collaboration agreement to strengthen international industrial competitiveness in quantum technology
Sept 25, 2025 18:37 HKT/SGT
SC Ventures and Fujitsu join forces to incubate Project Quanta
Sept 24, 2025 17:00 HKT/SGT
Kyushu Electric Power, IIJ, QTnet, 1Finity and Nautilus Technologies Launching Demonstration Project for Construction and Verification of Decentralized Digital Infrastructure
Sept 11, 2025 09:35 HKT/SGT
Kawasaki City becomes first dekokatsu subsidy municipality for promoting decarbonization lifestyle promotion project
Sept 8, 2025 13:28 HKT/SGT
Fujitsu develops generative AI reconstruction technology for optimized and energy-efficient AI models based on Takane LLM
Sept 3, 2025 09:58 HKT/SGT
Fujitsu, 1Finity and Arrcus sign strategic partnership agreement to deliver innovative network solutions for AI infrastructure
Aug 27, 2025 20:50 HKT/SGT
Fujitsu develops AI agent platform for the healthcare sector to enhance operational efficiency and ensure stable medical service provision
Aug 25, 2025 17:22 HKT/SGT
Shibaura Institute of Technology, Waseda University and Fujitsu develop quantum computer-based robot posture optimization
Aug 19, 2025 09:55 HKT/SGT
Fujitsu signs new licensing agreement with Palantir
Aug 6, 2025 10:00 HKT/SGT
Fujitsu's CHRO Roundtable Report 2025 highlights data-driven HRBP practices for human capital management
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: